Brian Shuch

14.7k total citations · 4 hit papers
200 papers, 6.9k citations indexed

About

Brian Shuch is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research. According to data from OpenAlex, Brian Shuch has authored 200 papers receiving a total of 6.9k indexed citations (citations by other indexed papers that have themselves been cited), including 165 papers in Pulmonary and Respiratory Medicine, 110 papers in Molecular Biology and 59 papers in Cancer Research. Recurrent topics in Brian Shuch's work include Renal cell carcinoma treatment (151 papers), Renal and related cancers (101 papers) and Cancer Genomics and Diagnostics (44 papers). Brian Shuch is often cited by papers focused on Renal cell carcinoma treatment (151 papers), Renal and related cancers (101 papers) and Cancer Genomics and Diagnostics (44 papers). Brian Shuch collaborates with scholars based in United States, Canada and United Kingdom. Brian Shuch's co-authors include Arie S. Belldegrun, Allan J. Pantuck, W. Marston Linehan, Fairooz F. Kabbinavar, Tobias Klatte, Jonathan Said, Jeffrey C. LaRochelle, Ramaprasad Srinivasan, Gennady Bratslavsky and Srinivas Vourganti and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Brian Shuch

194 papers receiving 6.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Understanding Pathologic Variants of Renal Cell Carcinoma: Distilling Therapeutic Opportunities from Biologic Complexity

2014 393 citations Brian Shuch et al. European Urology profile →
Magnetic Resonance Imaging/Ultrasound–Fusion Biopsy Significantly Upgrades Prostate Cancer Versus Systematic 12-core Transrectal Ultrasound Biopsy

2013 381 citations Mohummad Minhaj Siddiqui, Lambros Stamatakis et al. European Urology profile →
Epidemiology of Renal Cell Carcinoma: 2022 Update

2022 358 citations Maria I. Carlo, Ben Challacombe et al. European Urology profile →
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial

2021 170 citations Sumanta K. Pal, Catherine M. Tangen et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Brian Shuch United States	43	5.2k	3.7k	2.0k	1.4k	1.3k	200	6.9k
A. Ari Hakimi United States	45	4.9k 0.9×	4.4k 1.2×	2.9k 1.5×	2.1k 1.5×	1.3k 1.0×	229	8.3k
José A. Karam United States	43	4.7k 0.9×	3.4k 0.9×	1.8k 0.9×	1.5k 1.1×	2.5k 1.9×	274	7.0k
Lorenzo Marconi Portugal	30	5.5k 1.1×	3.5k 0.9×	1.3k 0.6×	1.2k 0.9×	1.6k 1.2×	59	6.4k
Milan Hora Czechia	32	7.2k 1.4×	5.0k 1.4×	1.8k 0.9×	1.3k 0.9×	2.0k 1.5×	236	8.3k
Arnaud Méjean France	43	3.9k 0.8×	2.6k 0.7×	1.2k 0.6×	1.4k 1.0×	2.0k 1.5×	226	7.1k
Richard E. Greenberg United States	44	4.6k 0.9×	3.0k 0.8×	1.2k 0.6×	1.1k 0.8×	2.2k 1.7×	200	7.1k
Stephan Störkel Germany	35	3.7k 0.7×	2.9k 0.8×	1.4k 0.7×	1.5k 1.1×	1.1k 0.8×	123	5.8k
Sanja Đačić United States	51	6.1k 1.2×	2.3k 0.6×	2.2k 1.1×	4.1k 2.9×	1.5k 1.1×	171	9.5k
Alessandro Volpe Italy	41	8.0k 1.5×	5.4k 1.5×	1.6k 0.8×	1.4k 1.0×	2.4k 1.9×	140	9.4k
David Y.T. Chen United States	38	3.6k 0.7×	3.1k 0.8×	1.0k 0.5×	808 0.6×	1.4k 1.1×	134	5.3k

Countries citing papers authored by Brian Shuch

Since Specialization

Citations

This map shows the geographic impact of Brian Shuch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Shuch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Shuch more than expected).

Fields of papers citing papers by Brian Shuch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian Shuch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Shuch. The network helps show where Brian Shuch may publish in the future.

Co-authorship network of co-authors of Brian Shuch

This figure shows the co-authorship network connecting the top 25 collaborators of Brian Shuch. A scholar is included among the top collaborators of Brian Shuch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian Shuch. Brian Shuch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kanabur, Pratik, Riccardo Campi, Maxine Tran, et al.. (2025). ‘ BJUI Clinical Dilemma’: the incidental small renal mass in a solitary kidney. British Journal of Urology. 135(3). 371–379.

Kim, Hyung L., Catherine M. Tangen, Ulka N. Vaishampayan, et al.. (2024). SWOG S1931 (PROBE): PHASE III RANDOMIZED TRIAL OF IMMUNE CHECKPOINT INHIBITOR (ICI) COMBINATION REGIMEN WITH OR WITHOUT CYTOREDUCTIVE NEPHRECTOMY (CN) IN ADVANCED RENAL CANCER [NCT04510597]. Urologic Oncology Seminars and Original Investigations. 42. S4–S4. 2 indexed citations

Choueiri, Toni K., Thomas Powles, David A. Braun, et al.. (2024). 45 INTerpath-004: A phase 2, randomized, double-blind study of pembrolizumab with V940 (mRNA-4157) or placebo in the adjuvant treatment of renal cell carcinoma. The Oncologist. 29(Supplement_1). S15–S15. 3 indexed citations

Paradkar, Sateja, Joseph Edmonds, Sam Friedman, et al.. (2024). NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion. Molecular Cancer Research. 22(10). 973–988. 1 indexed citations

Wilde, Blake R., Daiki Ueno, Edward D. Esplin, et al.. (2023). FH Variant Pathogenicity Promotes Purine Salvage Pathway Dependence in Kidney Cancer. Cancer Discovery. 13(9). 2072–2089. 19 indexed citations

Chervu, Nikhil, Sara Sakowitz, Arjun Verma, et al.. (2023). Disparate Utilization of Breast Conservation Therapy in the Surgical Management of Early-Stage Breast Cancer. Clinical Breast Cancer. 23(5). 561–566. 3 indexed citations

Shuch, Brian, et al.. (2022). CD70-Targeted Micelles Enhance HIF2α siRNA Delivery and Inhibit Oncogenic Functions in Patient-Derived Clear Cell Renal Carcinoma Cells. Molecules. 27(23). 8457–8457. 10 indexed citations

Sulkowski, Parker L., Sebastian Oeck, Yanfeng Liu, et al.. (2020). Oncometabolites suppress DNA repair by disrupting local chromatin signalling. Nature. 582(7813). 586–591. 200 indexed citations

Bergerot, Cristiane Decat, Dena Battle, Errol J. Philip, et al.. (2020). Fear of Cancer Recurrence in Patients With Localized Renal Cell Carcinoma. JCO Oncology Practice. 16(11). e1264–e1271. 17 indexed citations

10.

Carlo, Maria I., A. Ari Hakimi, Grant D. Stewart, et al.. (2019). Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights. European Urology. 76(6). 754–764. 76 indexed citations

11.

Xu, Yang, Paul Taylor, Joshua Andrade, et al.. (2018). Pathologic Oxidation of PTPN12 Underlies ABL1 Phosphorylation in Hereditary Leiomyomatosis and Renal Cell Carcinoma. Cancer Research. 78(23). 6539–6548. 14 indexed citations

12.

Ueno, Daiki, Zuoquan Xie, Marta Boeke, et al.. (2018). Genomic Heterogeneity and the Small Renal Mass. Clinical Cancer Research. 24(17). 4137–4144. 13 indexed citations

13.

Nguyen, Kevin A., Walter Hsiang, Kamyar Ghabili, et al.. (2018). Determinants of Active Surveillance in Patients With Small Renal Masses. Urology. 123. 167–173. 16 indexed citations

14.

Hofmann, Jonathan N., Qing Lan, Richard Cawthon, et al.. (2013). A Prospective Study of Leukocyte Telomere Length and Risk of Renal Cell Carcinoma. Cancer Epidemiology Biomarkers & Prevention. 22(5). 997–1000. 14 indexed citations

15.

Siddiqui, Mohummad Minhaj, Chris Ricketts, Srinivas Vourganti, et al.. (2013). Robot-Assisted Partial Cystectomy for Treatment of Bladder Paraganglioma. Videourology. 27(6). 3 indexed citations

16.

Chow, Wong‐Ho, Brian Shuch, W. Marston Linehan, & Susan S. Devesa. (2012). Racial disparity in renal cell carcinoma patient survival according to demographic and clinical characteristics. Cancer. 119(2). 388–394. 94 indexed citations

17.

Pouliot, Frédéric, et al.. (2011). Prospective Study Comparing Two Techniques of Renal Clamping in Laparoscopic Partial Nephrectomy: Impact on Perioperative Parameters. Journal of Endourology. 26(5). 509–514. 16 indexed citations

18.

Klatte, Tobias, Priya Rao, Michela de Martino, et al.. (2009). Cytogenetic Profile Predicts Prognosis of Patients With Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology. 27(5). 746–753. 151 indexed citations

19.

Shuch, Brian, Tobias Klatte, Stephen B. Riggs, et al.. (2008). Performance status and cytoreductive nephrectomy. Cancer. 113(6). 1324–1331. 45 indexed citations

20.

Osman, Iman, Maryann Mikhail, Brian Shuch, et al.. (2005). SERUM LEVELS OF SHED HER2/NEU PROTEIN IN MEN WITH PROSTATE CANCER CORRELATE WITH DISEASE PROGRESSION. The Journal of Urology. 174(6). 2174–2177. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact